IP Library › Granted Patent US 12,480,940
Granted Patent B2
US 12,480,940 · App. 17/055,829 · Granted Nov 25, 2025

Methods for isolating surface marker displaying agents

Inventor: David Routenberg (Gaithersburg, MD)
Assignee: MESO SCALE TECHNOLOGIES, LLC.
G01N33/5076C12N15/1006G01N33/54313G01N2333/705
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,480,940
App. No.
17/055,829
Granted
Nov 25, 2025
Kind
B2
Abstract

The invention relates to method and kits for highly specific isolation of extracellular vesicles (EVs) by targeting at least two EV surface markers. The invention further relates to methods and kits for analyzing EVs and their contents.

Claims (29)

1 . A kit for detecting an extracellular vesicle (EV) in a sample comprising, in one or more vials, containers, or compartments:

a. a surface comprising (i) a labile linker comprising a first restriction site, (ii) a capture reagent that specifically binds a first surface marker of the EV, wherein the capture reagent is bound to the labile linker, and (iii) an anchoring reagent comprising a first oligonucleotide;

b. a first binding reagent that specifically binds a second surface marker of the EV, wherein the first binding reagent comprises a second oligonucleotide comprising a first unique barcode sequence and a first hybridization sequence;

c. a second binding reagent that specifically binds a third surface marker of the EV, wherein the second binding reagent comprises a third oligonucleotide comprising a second unique barcode sequence, a second hybridization sequence, and a third hybridization sequence, and

d. an adaptor oligonucleotide comprising a second restriction site, a fourth unique barcode sequence, a region complementary to the first oligonucleotide, and a fourth hybridization sequence,

wherein the first hybridization sequence and the second hybridization sequence are complementary to each other,

wherein the third hybridization sequence and the fourth hybridization sequence are complementary to each other, and

wherein the first restriction site and the second restriction site are different.

2 . The kit of claim 1 , wherein the capture reagent comprises an antibody, antigen, ligand, receptor, oligonucleotide, hapten, epitope, mimitope, or aptamer.

3 . The kit of claim 1 , wherein the first binding reagent, the second binding reagent, or both comprises an antibody, antigen, ligand, receptor, oligonucleotide, hapten, epitope, mimitope, or aptamer.

4 . The kit of claim 1 , wherein the surface comprises a particle.

5 . The kit of claim 1 , wherein the surface comprises a well of a multi-well plate.

6 . The kit of claim 1 , wherein the surface comprises a plurality of distinct binding domains and the capture reagent and the anchoring reagent are located on two distinct binding domains on the surface.

7 . The kit of claim 5 , wherein the well comprises a plurality of distinct binding domains and the capture reagent and the anchoring reagent are located on two distinct binding domains within the well.

8 . The kit of claim 1 , wherein the surface comprises a plurality of distinct binding domains and the capture reagent and the anchoring reagent are located on the same binding domain on the surface.

9 . The kit of claim 5 , wherein the well comprises a plurality of distinct binding domains and the capture reagent and the anchoring reagent are located on the same binding domain within the well.

10 . The kit of claim 1 , wherein the capture reagent and the anchoring reagent are within 10 μm, 5 um, or 100 nm on the surface.

11 . The kit of claim 1 , wherein the surface comprises an electrode.

12 . The kit of claim 1 , wherein the first surface marker is CD9, CD63, or CD81.

13 . The kit of claim 1 , further comprising a lysis buffer.

14 . The kit of claim 1 , further comprising a ligase.

15 . The kit of claim 1 , further comprising a label.

16 . The kit of claim 1 , further comprising a first restriction endonuclease and a second restriction endonuclease.

17 . The kit of claim 1 , wherein at least one of the first, second, or third surface marker is specific to a central nervous system (CNS) EV.

18 . The kit of claim 1 , further comprising a polymerase.

19 . The kit of claim 1 , wherein the second oligonucleotide comprises a first amplification primer site and the adaptor oligonucleotide comprises a second amplification primer site.

20 . The kit of claim 1 , wherein the capture reagent comprises a third unique barcode sequence.

21 . The kit of claim 2 , wherein the capture reagent comprises an antibody or antigen binding fragment thereof.

22 . The kit of claim 3 , wherein the first binding reagent, the second binding reagent, or both, comprises an antibody or antigen binding fragment thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2020
From: ROUTENBERG, DAVID
To: MESO SCALE TECHNOLOGIES, LLC.
Reel/Frame 054383/0816 →
Continuity (3)
Provisional Application 62749640 · Oct 23, 2018
Provisional Application 62673043 · May 17, 2018
Related Publication 20210389304A1 · Dec 16, 2021
References Cited (78)
US 5238808A · Bard · 1993 [cited by applicant]
US 5240863A · Shibue et al. · 1993 [cited by applicant]
US 5641623A · Martin · 1997 [cited by applicant]
US 5846485A · Leland et al. · 1998 [cited by applicant]
US 6054274A · Sampson et al. · 2000 [cited by applicant]
US 6291187B1 · Kingsmore et al. · 2001 [cited by applicant]
US 6323009B1 · Lasken et al. · 2001 [cited by applicant]
US 6344329B1 · Lizardi · 2002 [cited by applicant]
US 6368801B1 · Faruqi · 2002 [cited by applicant]
US 6939720B2 · Chandler et al. · 2005 [cited by applicant]
US 6977722B2 · Wohlstadter et al. · 2005 [cited by applicant]
US 7842246B2 · Wohlstadter et al. · 2010 [cited by applicant]
US 10201812B2 · Glezer et al. · 2019 [cited by applicant]
US 10655162B1 · Alon et al. · 2020 [cited by applicant]
US 20100261292A1 · Glezer et al. · 2010 [cited by applicant]
US 20150119278A1 · Goetzl · 2015 [cited by applicant]
US 20150125477A1 · Kuttruff-Coqui et al. · 2015 [cited by applicant]
US 20160003835A1 · Halbert et al. · 2016 [cited by applicant]
US 20170211133A1 · Landegren et al. · 2017 [cited by applicant]
US 20190203275A1 · Frisen et al. · 2019 [cited by applicant]
US 20210382043A1 · Routenberg et al. · 2021 [cited by applicant]
US 20230349920A1 · Routenberg et al. · 2023 [cited by applicant]
US 20250035615A1 · Routenberg · 2025 [cited by applicant]
EP 3246703A1 · 2017 [cited by applicant]
WO 2015175856A1 · 2010 [cited by applicant]
WO 2011062933A2 · 2011 [cited by applicant]
WO 2015130956A2 · 2015 [cited by applicant]
WO 2016193695A1 · 2016 [cited by applicant]
WO 2017053516A1 · 2017 [cited by applicant]
WO 2017124000A1 · 2017 [cited by applicant]
WO 2018213847A1 · 2018 [cited by applicant]
WO 2019014486A1 · 2019 [cited by applicant]
WO 2019113499A1 · 2019 [cited by applicant]
WO 2019222708A2 · 2019 [cited by applicant]
WO 2020086751A1 · 2020 [cited by applicant]
WO 2020142313A1 · 2020 [cited by applicant]
WO 2022011197A1 · 2022 [cited by applicant]
WO 2022051481A2 · 2022 [cited by applicant]
WO 2023212315A2 · 2023 [cited by applicant]
Bombera et al. (DNA-directed capture of primary cells from a complex mixture and controlled orthogonal release monitored by SPR imaging. Biosens Bioelectron. Mar. 15, 2012;33(1):10-6). (Year: 2012). [cited by examiner]
Zhang HG, Liu C, Su K, Yu S, Zhang L, Zhang S, Wang J, Cao X, Grizzle W, Kimberly RP. A membrane form of TNF-alpha presented by exosomes delays T cell activation-induced cell death. J Immunol. Jun. 15, 2006;176(12):7385… [cited by examiner]
Aureli, M. et al., “GM Ganglioside: Past Studies and Future Potential”, Mol. Neurobiol. 53:1824-1842 (2016). [cited by applicant]
Lauc, G. et al., “Shedding and Uptake of Gangliosides and Glycosylphosphatidylinositol-Anchored Proteins”, Biochimica et Biophysica Acta 1760(4):584-602 (2006). [cited by applicant]
Koliha et al., “A novel multiplex bead-based platform highlights the diversity of extracellular vesicles,” Journal of Extracellular Vesicles, 5:29975 (2016). [cited by applicant]
International Search Report and Written Opinion issued Nov. 20, 2019, in International Appln No. PCT/US2019/032995. [cited by applicant]
Armstrong et al., “Extracellular Vesicles and the Promise of Continuous Liquid Biopsies,” Journal of Pathology and Translational Medicine 52:1-8 (2018). [cited by applicant]
Baner et al., “Signal amplification of padlock probes by rolling circle replication,” Nucleic Acids Res. 26:5073-5078 (1998). [cited by applicant]
Bugeon et al., “Costimulation of Cells,” Am. J. Respir. Crit. Care Med. 162:S164-S168 (2000). [cited by applicant]
Dean et al., “Rapid Amplification of Plasmid and Phage DNA Using Phi29 DNA Polymerase and Multiply-Primed Rolling Circle Amplification,” Genome Res. 11:1095-1099 (2001). [cited by applicant]
Eason et al., “Characterization of synthetic DNA bar codes in Saccharomyces cerevisiae gene-deletion strains,” Proc Natl Acad Sci USA 101(30):11046-11051 (2004). [cited by applicant]
Faruqi et al., “High-throughput genotyping of single nucleotide polymorphisms with rolling circle amplification,” BMC Genomics 2:4 (2000). [cited by applicant]
Fredriksson et al., “Multiplexed protein detection by proximity ligation for cancer biomarker validation,” Nature Methods 4(4):327-329 (2007). [cited by applicant]
Gardiner et al., “Techniques used for the isolation and characterization of extracellular vesicles: Results of a worldwide survey,” Journal of Extracellular Vesicles 5(1):32945 (2016). [cited by applicant]
Hein et al., “Click Chemistry, a Powerful Tool for Pharmaceutical Sciences,” Pharm. Res. 25(10):2216-2230 (2008). [cited by applicant]
Hill et al., “The bio-barcode assay for the detection of protein and nucleic acid targets using DTT-induced ligand exchange,” Nature Protocols 1(1):324-336 (2006). [cited by applicant]
Hodge et al., “Costimulatory Molecules as Adjuvants for Immunotherapy,” Frontiers in Bioscience 11:788-803 (2006). [cited by applicant]
Kalra et al., “Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation,” PLoS Biol 10(12):e1001450 (2012). [cited by applicant]
Kim et al., “EVpedia: an integrated database of high-throughput data for systemic analyses of extracellular vesicles,” Journal of Extracellular Vesicles 2:20384 (2013). [cited by applicant]
Lizardi et al., “Mutation detection and single-molecule counting using isothermal rolling-circle amplification,” Nature Genetics 19:225-232 (1998). [cited by applicant]
Mathivanan et al., “ExoCarta: a compendium of exosomal proteins and RNA,” Proteomics 9:4997-5000 (2009). [cited by applicant]
Mathivanan et al., “ExoCarta 2012: database of exosomal proteins RNA and lipids,” Nucleic Acids Res. 40(D1): D1241-D1244 (2012). [cited by applicant]
Nallur et al., “Signal amplification by rolling circle amplification on DNA microarrays,” Nucleic Acids Res. 29:e118 (2001). [cited by applicant]
Nam et al., “Nanoparticle-Based Bio-Bar Codes for the Ultrasensitive Detection of Proteins,” Science 301(5641):1884-1886 (2003). [cited by applicant]
Schweitzer et al., “Immunoassays with rolling circle DNA amplification: a versatile platform for ultrasensitive antigen detection,” Proc Natl Acad Sci USA 97:10113-10119 (2000). [cited by applicant]
Schweitzer et al., “Multiplexed protein profiling on microarrays by rolling-circle amplification,” Nature Biotechnol. 20:359-365 (2002). [cited by applicant]
Simpson et al., “ExoCarta as a resource for exosomal research,” Journal of Extracellular Vesicles 1:18374 (2012). [cited by applicant]
Thermofisher, “Crosslinking Technical Handbook,” Oct. 2012 printed in the U.S. [cited by applicant]
Winzeler et al., “Functional characterization of the [cited by applicant]
International Search Report in PCT/US19/57713, dated Dec. 20, 2019. [cited by applicant]
International Search Report in PCT/US2021/048849 dated Feb. 25, 2022. [cited by applicant]
International Search Report in PCT/US2023/020399 dated Oct. 26, 2023. [cited by applicant]
Darmanis et al., “ProteinSeq: High-Performance Proteomic Analyses by Proximity Ligation and Next Generation Sequencing,” PLoS One 6(9):e25583 (2011). [cited by applicant]
Hammond et al., “Profiling Cellular Protein Complexes by Proximity Ligation with Dual Tag Microarray Readout,” PLoS One 7(7):e40405 (2012). [cited by applicant]
Lof et al., Detection of Extracellular Vesicles Using Proximity Ligation Assay with Flow Cytometry Readout-ExoPLA, Current Protocols in Cytometry 4(8):1-10 (2017). [cited by applicant]
Schallmeiner et al., “Sensitive protein detection via triple-binder proximity ligation assays,” Nature Methods 4(2):135-137 (2007). [cited by applicant]
Tavoosidana et al., Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer, 108(21):8809-8814 (2011). [cited by applicant]
Non-final Office Action in U.S. Appl. No. 17/287,341, dated Nov. 19, 2024. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 17/287,341, dated Sep. 8, 2025. [cited by applicant]
Cited By (1)
US 12,631,624